Literature DB >> 17119891

[Endovascular treatment for intracranial stenoses. A common statement by neurologists and neuroradiologists].

J Berkefeld1, G F Hamann, R du Mesnil, W Kurre, H Steinmetz, F E Zanella, M Sitzer.   

Abstract

Intracranial stenoses cause 5-10% of all strokes and are increasingly detected by means of modern imaging methods. The stroke danger of high-grade symptomatic stenoses is relatively high, with an annual risk of approximately 10% under medical treatment. Coumadin increases the risk of hemorrhage, and after risk/benefit considerations, antiplatelets should be preferred for antithrombotic therapy. Despite optimized medical treatment, a small group of patients with recurrent symptoms or symptomatic stenoses without adequate collateral supply probably carry higher spontaneous stroke risk and may be considered for intracranial stenting, which itself is associated with procedural risks of up to 10%. Currently published case series show relatively high complication rates as a major drawback of endovascular treatment, mainly strokes after occlusion of perforating branches extending from the stenotic vessel segment or hemorrhagic complications. According to data from smaller feasibility studies, stroke rates in follow-up after successful stenting seem to be low. The average rate of high-grade restenosis with possible indication for reintervention is 10%. Improvements in endovascular treatment aim at reducing vessel wall trauma during balloon angioplasty by underdilatation or the use of self-expanding stents. Until complication rates are dependably reduced to values of 5-6%, indication for endovascular treatment should be restricted to patients without therapeutic alternatives. According to limited data with large variation between different studies, a prospective multicentric registry is proposed for systematic evaluation and further development of the method.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119891     DOI: 10.1007/s00115-006-2182-z

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  38 in total

1.  Protective role of chronic statin therapy in reducing myocardial damage during percutaneous coronary intervention.

Authors:  Carla Auguadro; Mariella Manfredi; Filippo Scalise; Andrea Mortara; Giuseppe Specchia
Journal:  J Cardiovasc Med (Hagerstown)       Date:  2006-06       Impact factor: 2.160

2.  Percutaneous transluminal cerebral angioplasty: serial angiographic follow-up after successful dilatation.

Authors:  T Mori; K Mori; M Fukuoka; M Arisawa; S Honda
Journal:  Neuroradiology       Date:  1997-02       Impact factor: 2.804

3.  Association of the metabolic syndrome with intracranial atherosclerotic stroke.

Authors:  O Y Bang; J W Kim; J H Lee; M A Lee; P H Lee; I S Joo; K Huh
Journal:  Neurology       Date:  2005-07-26       Impact factor: 9.910

4.  Race and sex differences in the distribution of cerebral atherosclerosis.

Authors:  R J Wityk; D Lehman; M Klag; J Coresh; H Ahn; B Litt
Journal:  Stroke       Date:  1996-11       Impact factor: 7.914

5.  Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy.

Authors:  V N Thijs; G W Albers
Journal:  Neurology       Date:  2000-08-22       Impact factor: 9.910

6.  Natural history of stenosis from intracranial atherosclerosis by serial angiography.

Authors:  P T Akins; T K Pilgram; D T Cross; C J Moran
Journal:  Stroke       Date:  1998-02       Impact factor: 7.914

7.  Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results.

Authors: 
Journal:  Stroke       Date:  2004-04-22       Impact factor: 7.914

8.  Angioplasty for symptomatic intracranial stenosis: clinical outcome.

Authors:  Michael P Marks; Joan C Wojak; Firas Al-Ali; Mahesh Jayaraman; Mary L Marcellus; John J Connors; Huy M Do
Journal:  Stroke       Date:  2006-02-23       Impact factor: 7.914

9.  Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study.

Authors:  R L Sacco; D E Kargman; Q Gu; M C Zamanillo
Journal:  Stroke       Date:  1995-01       Impact factor: 7.914

10.  Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group.

Authors: 
Journal:  Stroke       Date:  1998-07       Impact factor: 7.914

View more
  4 in total

1.  Stent angioplasty of intracranial stenosis: single center experience of 54 cases.

Authors:  F Dorn; S Prothmann; S Wunderlich; T Liebig
Journal:  Clin Neuroradiol       Date:  2011-09-21       Impact factor: 3.649

2.  Endovascular therapy of symptomatic intracranial stenosis in patients with impaired regional cerebral blood flow or failure of medical therapy.

Authors:  V Puetz; G Gahn; U Becker; D Mucha; A Mueller; N U Weir; B Wiedemann; R von Kummer
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

Review 3.  Intracranial stenting of atherosclerotic stenoses: current status and perspectives.

Authors:  Joachim Berkefeld; Friedhelm E Zanella
Journal:  Klin Neuroradiol       Date:  2009-05-15

4.  Treatment of symptomatic high-grade intracranial stenoses with the balloon-expandable Pharos stent: initial experience.

Authors:  W Kurre; J Berkefeld; M Sitzer; T Neumann-Haefelin; R du Mesnil de Rochemont
Journal:  Neuroradiology       Date:  2008-04-26       Impact factor: 2.804

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.